UBI Pharma Inc is a Taiwan-based company mainly engaged in development and manufacturing of protein drugs and special dosage-form drugs. The Company is engaged in research and development, manufacturing and sales of protein drugs and special dosage-form drugs, contract manufacturing of pharmaceuticals, and provision of contract research services. The protein drug product line includes erythropoietin (UB-851) biosimilar drugs, innovative long-acting erythropoietin (UB-852), innovative long-acting granular ball community stimulating hormone (UB-853), and others used to treat anemia, neutropenia. The small molecule new drug product line includes B-Raf kinase inhibitor (UB-941) for the treatment of melanoma. The special scientific name drug product line includes tablets Olanzapine and Nevirapin for the treatment of schizophrenia and AIDS, and injections Granisetronl and Meropenen for the treatment of bacterial infections. It sells products in the domestic market and overseas markets.